Canada

Precision NanoSystems

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

CanSino, Precision NanoSystems to co-develop COVID-19 RNA Vaccine

Lead Product(s): COVID-19 mRNA-LNP vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: CanSino Biologics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 21, 2020

Details:

Under this collaboration, PNI will be responsible for development of the mRNA-LNP vaccine and CanSinoBIO will be responsible for pre-clinical testing, human clinical trials, regulatory approval and commercialization.

Purdue Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Purdue-Developed Nanomaterial Significantly Enhances Potential COVID-19 Therapeutic

Lead Product(s): Niclosamide

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

Purdue University scientist Yuan Yao’s laboratory has developed a solution, a plant-based, highly potent nanoparticle called OHPP (octenylsuccinate hydroxypropyl phytoglycogen) that can solubilize and enable niclosamide.

VIDO-InterVac

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19

Lead Product(s): Plant based vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: ZYUS Life Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 07, 2020

Details:

ZYUS will leverage its bio-pharmaceutical plant technology platform and expertise to develop and express a protein that VIDO-InterVac has identified as a potential antigen for a COVID-19 vaccine.

AbCellera

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

AbCellera Gets Funding for Drug Discovery Technology That Identifies Antibodies for Potential Use in drugs to treat and prevent COVID-19.

Lead Product(s): COVID-19 antibodies

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Government of Canada

Deal Size: $175.6 million Upfront Cash: Undisclosed

Deal Type: Funding May 03, 2020

Details:

Fund will expand AbCellera's efforts, as more than 500 specific human anti-SARS-CoV-2 antibodies have been established as part of a partnership with the Vaccine Research Center.

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

Details:

The study will be an adaptive pilot to pivotal trial design based on WHO guidance documents to assess whether Ifenprodil will improve clinical symptoms and minimize mortality in COVID-19 infection.

Bausch Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Bausch Health Begins Clinical Study in Canada Evaluating Virazole in Combo with Standard of Care Therapy for COVID-19 Treatment

Lead Product(s): Ribavirin

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2020

Details:

The company believes that since ribavirin is a synthetic nucleoside, It may work to stop viral replication and VIRAZOLE may be effective in reducing the severity of COVID-19 infection.

Laurent Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Laurent Pharmaceuticals Joins Battle Against COVID-19

Lead Product(s): Fenretinide

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 09, 2020

Details:

Laurent Pharmaceuticals is planning to test its lead drug LAU-7b in patients with COVID-19 disease, as part of a Phase 2 clinical trial.

Revive Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Revive Therapeutics Announces Filing of FDA Pre-IND Meeting

Lead Product(s): Bucillamine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 03, 2020

Details:

Revive has filed its Pre-Investigational New Drug meeting request with the U.S. Food and Drug Administration for Bucillamine in the treatment of the coronavirus disease.

Covar Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19)

Lead Product(s): SACT-COV19

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Aptorum

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 30, 2020

Details:

Aptorum with Covar Pharmaceuticals and in alliance with the University of Hong Kong plans to perform more preclinical experiments on selected small drug molecules to combat COVID-19 infection.

Resverlogix Corp

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Resverlogix Clinical Candidate Apabetalone Featured As A Potential Covid-19 Treatment In Recent Publication

Lead Product(s): Apabetalone

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2020

Details:

The study demonstrates apabetalone to inhibit specialized proteins called bromodomain and extraterminal domain proteins from interacting with a SARS-CoV-2 viral protein.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Precision NanoSystems

CanSino, Precision NanoSystems to co-develop COVID-19 RNA Vaccine

Purdue Pharma

Purdue-Developed Nanomaterial Significantly Enhances Potential COVID-19 Therapeutic

VIDO-InterVac

ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19

AbCellera

AbCellera Gets Funding for Drug Discovery Technology That Identifies Antibodies for Potential Use in drugs to treat and prevent COVID-19.

Algernon Pharmaceuticals

Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial

Bausch Health

Bausch Health Begins Clinical Study in Canada Evaluating Virazole in Combo with Standard of Care Therapy for COVID-19 Treatment

Laurent Pharmaceuticals

Laurent Pharmaceuticals Joins Battle Against COVID-19

Revive Therapeutics

Revive Therapeutics Announces Filing of FDA Pre-IND Meeting

Covar Pharmaceuticals

Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19)

Resverlogix Corp

Resverlogix Clinical Candidate Apabetalone Featured As A Potential Covid-19 Treatment In Recent Publication